CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...
In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5i treatment Data from this Phase 2 clinical study is expected by end of calendar year 2024 Publishe...
Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024 Additiona...
Investors might want to bet on The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side anal...
Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P...
CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the o...
Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's me...
CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ac...
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom en...
Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P...
On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met , Statistical Significance (P...